News

Click here to sign up to the OPDC News Mailing list

Inside the Wade-Martins lab

Inside the Wade-Martins lab

Posted 11/04/2019

This week Oxford University's Department of Physiology, Anatomy and Genetics is marking World Parkinson's Day, which takes place on Thursday 11 April 2019, with an inside look into the Wade-Martins Laboratory. The Wade-Martins Group conducts critical research into several neurodegenerative diseases, and makes up part of the OPDC with its work into Parkinson's, with the aim to understand the molecular mechanisms of these disorders and help ...

OPDC study finds mutations in the gene LRRK2 affect normal cell function.

OPDC study finds mutations in the gene LRRK2 affect normal cell function.

Posted 11/04/2019

A new study from OPDC Career Development Fellow Natalie Connor-Robson investigates how mutations in the gene LRRK2, which are known to cause Parkinson’s, effect normal cell function. We generated dopaminergic neurons, the cells that are affected in Parkinson’s, from stem cells reprogrammed using skin samples donated by people with Parkinson’s who carry LRRK2 mutations. These neurons were used for in depth analysis which showed the most altered ...

OPDC research featured in OxfordAI videos

OPDC research featured in OxfordAI videos

Posted 21/12/2018

The videos focus on two of our projects to use new technology to better understand the progression of Parkinson's. The first highlights our sleep study which aims to make it possible to monitor sleep in the home using wearable devices. The second features our smartphone app which monitors different motor symptoms of Parkinson's to improve our understanding of Parkinson's and help us improve treatments.    

New OPDC study on neurons grown from skin samples reveals key molecular changes in people with Parkinson's

New OPDC study on neurons grown from skin samples reveals key molecular changes in people with Parkinson's

Posted 25/02/2019

In a new study from OPDC researchers we generated dopaminergic neurons, the cells that are affected in Parkinson’s, from stem cells reprogrammed using skin samples donated by people with Parkinson’s who have changes in the alpha-synuclein gene (alpha-synuclein mutation and triplication). We observed that cells produced from these people with Parkinson’s accumulated detrimental alpha-synuclein species in the cells. The cells also showed problems ...

Oxford Parkinson's Disease Centre members raise funds for their research and enjoy a pub quiz in the process!

Oxford Parkinson's Disease Centre members raise funds for their research and enjoy a pub quiz in the process!

Posted 03/01/2019

Parkinson’s researchers Dayne Beccano-Kelly, Siv Vingill and Nora Bengoa-Vergniory, along with OPDC administrator Melanie Witt travelled to the Royal Oak, Goodworth Clatford in Andover for a quiz night in aid of Parkinson’s research. During the night, held on Wednesday 12 December, OPDC supporters Bobbie Coelho, Mary Doherty and Dawn Huntly presented a cheque for £1,500 to support Parkinson’s research. The funds have been raised by a number ...

Sleep study seeks people with Parkinson's and/or RBD

Sleep study seeks people with Parkinson's and/or RBD

Posted 14/11/2018

Researchers at OPDC are embarking on a new five-year study looking at the links between a condition known as Rapid Eye Movement Sleep Behaviour Disorder (RBD) and Parkinson’s. Funded by the NIHR Oxford Biomedical Research Centre. The study seeks to improve the remote diagnosis and monitoring of sleep problems at home and is currently looking for people with Parkinson's and RBD to take part. RBD is a sleep problem where the switch that ...

Experimental cancer drug shows promise for Parkinson’s

Experimental cancer drug shows promise for Parkinson’s

Posted 29/11/2018

A drug originally developed for prostate cancer may have exciting potential for treating Parkinson’s, according to our new research published in Cell Stem Cell. The study, funded by Parkinson’s UK, suggests that the drug, tasquinimod, which is not yet on the market, works by controlling genes that may cause Parkinson’s. This happens when the drug interacts with a protein inside brain cells. The team here at the Oxford Parkinson’s Disease ...

Precision medicine for Parkinson’s, how close are we?

Precision medicine for Parkinson’s, how close are we?

Posted 28/11/2018

OPDC Medical statistician Michael Lawton has been working on a collaboration with the OPDC and Tracking Parkinson's cohorts to better define Parkinson's. His research has revealed 4 possible subtypes of the condition.

2018 OPDC Talks

2018 OPDC Talks

Posted 26/11/2018

We are pleased to annouced you can now watch the talks from the 2018 OPDC Participant's day online. The presentations, from September 10th, 2018 cover a range of subjects including our interest the link between sleep and Parkinson's, Parkinson’s dyskinesia, and drug discovery. We also welcomed Djordje Gveric from the Parkinson's UK Brain bank to tell us about the process and it's value.  Watch the talks  

One common variation in genetics can increase Parkinson’s risk

One common variation in genetics can increase Parkinson’s risk

Posted 09/11/2018

Work with OPDC from a DPhil project supported by the Oxford branch of Parkinson’s UK has been published in the journal Stem Cell Reports. The project, carried out under the supervision of OPDC’s Richard Wade-Martins focussed on the MAPT (microtubule-associated protein tau) gene, which provides the code for a set of six proteins called ‘tau’, and each of these six tau proteins is made from a different messenger RNA transcript made from the MAPT ...